Related references
Note: Only part of the references are listed.Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Renata Zajaczkowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy
Alex Molassiotis et al.
BRAIN AND BEHAVIOR (2019)
Tapentadol for neuropathic pain: a review of clinical studies
Ulderico Freo et al.
JOURNAL OF PAIN RESEARCH (2019)
Tapentadol: an overview of the safety profile
Enrico Polati et al.
JOURNAL OF PAIN RESEARCH (2019)
AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions
Judith A. Paice et al.
JOURNAL OF PAIN (2017)
Tapentadol in neuropathic pain cancer patients: a prospective open label study
Edvina Galie et al.
NEUROLOGICAL SCIENCES (2017)
Chemotherapy-Induced Peripheral Neuropathy: A Current Review
Nathan P. Staff et al.
ANNALS OF NEUROLOGY (2017)
Chemotherapy-induced peripheral neuropathy: Current status and progress
Jamie R. Brewer et al.
GYNECOLOGIC ONCOLOGY (2016)
How to diagnose neuropathic pain? The contribution from clinical examination, pain questionnaires and diagnostic tests
S. La Cesa et al.
NEUROLOGICAL SCIENCES (2015)
Chemotherapy-induced neuropathy: A comprehensive survey
N. C. Miltenburg et al.
CANCER TREATMENT REVIEWS (2014)
The Mu-Opioid Receptor Agonist/Noradrenaline Reuptake Inhibition (MOR-NRI) Concept in Analgesia: The Case of Tapentadol
Thomas M. Tzschentke et al.
CNS DRUGS (2014)
The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients
J. S. Hong et al.
CURRENT ONCOLOGY (2014)
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
Marta Seretny et al.
PAIN (2014)
Reporting of Noninferiority and Equivalence Randomized Trials Extension of the CONSORT 2010 Statement
Gilda Piaggio et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Objective pain diagnostics: Clinical neurophysiology
L. Garcia-Larrea
NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY (2012)
Clinical usefulness of laser evoked potentials
M. Valeriani et al.
NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY (2012)
Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods
H. J. Gerbershagen et al.
BRITISH JOURNAL OF ANAESTHESIA (2011)
NeuPSIG guidelines on neuropathic pain assessment
Maija Haanpaa et al.
PAIN (2011)
EFNS guidelines on neuropathic pain assessment: revised 2009
G. Cruccu et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?
Hans G. Kress
EUROPEAN JOURNAL OF PAIN (2010)
Recommendations for the clinical use of somatosensory-evoked potentials
G. Cruccu et al.
CLINICAL NEUROPHYSIOLOGY (2008)
Pain: a review of three commonly used pain rating scales
A Williamson et al.
JOURNAL OF CLINICAL NURSING (2005)
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20
TJ Postma et al.
EUROPEAN JOURNAL OF CANCER (2005)
Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)
D Bouhassira et al.
PAIN (2005)